Strategies for Rotation between Gabapentinoids in the Inpatient Setting

References

• Parke-Davis. Neurontin® (gabapentin) [package insert]. New York, NY: Parke-Davis, Division of Pfizer; 2017.
   Google Scholar
• Parke-Davis. Lyrica® (pregabalin) [package insert]. New York, NY: Parke-Davis, Division of Pfizer; 2019.
   Google Scholar
• Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–9. doi:10.2165/11536200-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Fauer AJ, Davis MA, Choi SW, Wallner LP, Friese CR. Use of gabapentinoid medications among US adults with cancer, 2005-2015. Support Care Cancer. 2020;28(1):5–8. doi:10.1007/s00520-019-05100-9.
   PubMed Web of Science ®Google Scholar
• Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010;11(3):456–65. doi:10.1111/j.1526-4637.2009.00796.x.
   PubMed Web of Science ®Google Scholar
• Saldaña MT, Pérez C, Navarro A, Masramón X, Rejas J. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. Clin Drug Invest. 2012; 32(6):401–12.
   PubMed Web of Science ®Google Scholar
• Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med. 2011;12(7):1112–6. doi:10.1111/j.1526-4637.2011.01162.x.
   PubMed Web of Science ®Google Scholar
• McQuoid P. Switching from gabapentin to pregabalin. N Z Med J. 2019;132(1491):101–3.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Budhwani MN, Wesche DL. Gabapentin to pregabalin therapy transition: a pharmacokinetic simulation. Am J Ther. 2013;20(1):32–6. doi:10.1097/MJT.0b013e318250f80e.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21. doi:10.1016/j.jpain.2007.09.005.
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018;101:87–106. doi:10.1016/j.jclinepi.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017;15(1):35. doi:10.1186/s12916-016-0775-3.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137–50. doi:10.1016/j.eplepsyres.2006.09.008.
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271(10):5768–76. doi:10.1074/jbc.271.10.5768.
   PubMed Web of Science ®Google Scholar
• Calandre EP, Rico-Villademoros F, Slim M. Alpha2 delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16(11):1263–77. doi:10.1080/14737175.2016.1202764.
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–83. doi:10.1177/0091270003251119.
   PubMed Web of Science ®Google Scholar
• Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56(2):154–9. doi:10.1038/clpt.1994.118.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Kaya A, Bozalan R, Aydogan T, Uz B, Isik A, Akcay A. Gabapentin induced edema in a geriatric patient. Clin Neuropharmacol. 2006;29(3):186.
   PubMed Web of Science ®Google Scholar
• Gallagher R, Apostle N. Peripheral edema with pregabalin. CMAJ. 2013;185(10):E506. doi:10.1503/cmaj.121232.
   PubMed Web of Science ®Google Scholar
• Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85. doi:10.1186/1471-2296-11-85.
   PubMed Web of Science ®Google Scholar
• Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2–3):123–7. doi:10.1016/S0920-1211(00)00117-0.
   PubMed Web of Science ®Google Scholar
• Guay DRP. Pregabalin in neuropathic pain: a more ‘pharmaceutically elegant” gabapentin? Am J Geritr Pharmacother. 2005;3(4):274–87. doi:10.1016/j.amjopharm.2005.12.008.
   PubMedGoogle Scholar
• Page RL, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med. 2008;9(9):922–5.
   Google Scholar